Newest Treatments for Hepatitis C, Genotype 1

CTAF

CTAF assessed the comparative effectiveness and value of multiple new, all-oral direct-acting antiviral agent (DAA) regimens for the treatment of hepatitis C. The review covers treatments under review by the FDA, including those developed by Gilead Sciences, Inc., AbbVie Inc., and Bristol-Myers Squibb Co. CTAF examined the first two DAAs approved for treating hepatitis C (sofosbuvir and simeprevir) at its March 2014 meeting, and the December 2014 meeting furthered discussion to help clinicians, patients, and policymakers understand the evolving evidence base on how best to treat hepatitis C. A policy roundtable discussion focused on the issue of drug pricing and payment models for costly drugs.

Key Dates

Associated Materials

11/17/2014

11/17/2014

12/08/2014

Public comments received on the Draft Evidence Report.


12/08/2014

12/18/2014

12/18/2014

01/30/2015

01/30/2015
Action Guide For Patients

01/30/2015
Action Guide For Clinicians

01/30/2015
Action Guide For Payers and Policymakers